A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer

The present study aimed to evaluate the anti-tumor efficacy of the epidermal growth factor receptor (EGFR)-targeting recombinant fusion protein Fv-LDP-D3 and its antibody-drug conjugate Fv-LDP-D3-AE against esophageal cancer. Fv-LDP-D3, consisting of the fragment variable (Fv) of an anti-EGFR antibo...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Shiming, Zhao, Chunyan, Tao, Hongyu, Sheng, Weijin, Gao, Ruijuan, Liu, Xiujun, Zhen, Yongsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048960/
https://www.ncbi.nlm.nih.gov/pubmed/35416106
http://dx.doi.org/10.1080/10717544.2022.2063454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048960/
https://www.ncbi.nlm.nih.gov/pubmed/35416106
http://dx.doi.org/10.1080/10717544.2022.2063454

Ejemplares similares